Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin, gemcitabine, and exisulind in treating patients who have advanced non-small cell lung cancer.
Checked against the public recordLast updated Jun 15, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Eastern Cooperative Oncology Group
- Interventions being studied
- Drug: carboplatin; Drug: exisulind; Drug: gemcitabine hydrochloride
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer (NSCLC) * Unresectable stage IIIB (e.g., pleural effusion) not suitable for combined modality therapy OR * Stage IV * Prior brain metastases are allowed provided the following are true: * Patient completed radiotherapy and/or surgery at least 3 weeks prior to study * Objective evidence of resolution or significant improvement of brain lesions exists on follow-up CT scan or MRI * Patient is neurologically improved or stable PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 Life expectancy: * Not specified Hematopoietic: * Absolute granulocyte count at least 1,500/mm\^3 * WBC at least 3,000/mm\^3 * Hemoglobin at least 9 g/L * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.25 mg/dL * SGOT no greater than 1.5 times upper limit of normal Renal: * Creatinine no greater than 2.0 mg/dL OR * Creatinine clearance at least 50 mL/min Cardiovascular: * No prior uncontrolled cardiovascular disease * No hospitalization for acute myocardial infarction, arrhythmia, or congestive heart failure within the past 3 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective nonhormonal contraception * No serious active infection * No dementia or active psychoses * No other prior malignancy except nonmetastatic nonmelanoma skin cancer, carcinoma in situ of the cervix, or cancer curatively treated with surgery or small-field radiotherapy within the past 5 years PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * At least 3 weeks since prior radiotherapy Surgery: * See Disease Characteristics Other: * At least 1 month since prior investigational agents * More than 7 days since prior aspirin, sulindac, cyclo-oxygenase-2 (COX-2) inhibitors, or nonsteroidal anti-inflammatory drugs (except ibuprofen or naproxen) * No concurrent sulindac or COX-2 inhibitors
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama at Birmingham Comprehensive Cancer CenterBirmingham, Alabama
- CCOP - Scottsdale Oncology ProgramScottsdale, Arizona
- City of Hope Comprehensive Cancer CenterDuarte, California
- Veterans Affairs Medical Center - Palo AltoPalo Alto, California
- Stanford University Medical CenterStanford, California
- CCOP - Colorado Cancer Research Program, Inc.Denver, Colorado
- CCOP - Christiana Care Health ServicesWilmington, Delaware
- MBCCOP-Howard University Cancer CenterWashington D.C., District of Columbia
- Veterans Affairs Medical Center - GainesvilleGainesville, Florida
- Veterans Affairs Medical Center - MiamiMiami, Florida
- H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
- Veterans Affairs Medical Center - Tampa (Haley)Tampa, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 15, 2023. Always confirm current availability with the study team.